OSEL Devices Ltd

Q1 FY26Healthcare Equipment & Supplies

OSEL Devices Q1 FY26 earnings call: Revenue & Margins

Q1 FY26 investor presentation: what the company reported on revenue, margins and projects.

Price₹391

Market cap₹648 Cr

P/E22.1

Updated24 Sept 2026

Read4 min read

Based on OSEL Devices Ltd's Q1 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.

The short version

FY25 total income (revenue) was ₹18,660.07 lakhs, up 41% YoY from ₹13,268.52 lakhs in FY24. EBITDA: ₹3,352.82 Lakhs in FY25 vs ₹2,288.29 Lakhs in FY24, a 47% YoY increase - EBITDA Margin: 17.97% in FY25 vs 17.25% in FY24, a 4% YoY increase - Profit After Tax (PAT): ₹2,005.27 Lakhs in FY25 vs ₹1,268.41 Lakhs in FY24, a 58% YoY increase - PAT Margin: 10.75% in FY25 vs 9.56% in FY24, a 12% YoY increase - Explicit Margin Outlook: No specific forward-looking margin guidance mentioned in the presentation.

From OSEL Devices Ltd's Q1 FY26 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

FY25 total income (revenue) was ₹18,660.07 lakhs, up 41% YoY from ₹13,268.52 lakhs in FY24.
EBITDA grew 47% YoY to ₹3,352.82 lakhs in FY25 from ₹2,288.29 lakhs in FY24.
PAT increased 58% YoY to ₹2,005.27 lakhs in FY25 from ₹1,268.41 lakhs in FY24.
EPS rose 30% YoY to ₹14.31 in FY25 from ₹10.99 in FY24.
Segment revenue mix FY25: Hearing Aids 55%, LED Displays 45%.
Segment Sales Growth FY24 to FY25: Hearing Aids 18%, LED Displays 82%.

2 more points management made on revenue & sales performance

Profitability & Margins

EBITDA: ₹3,352.82 Lakhs in FY25 vs ₹2,288.29 Lakhs in FY24, a 47% YoY increase
EBITDA Margin: 17.97% in FY25 vs 17.25% in FY24, a 4% YoY increase
Profit After Tax (PAT): ₹2,005.27 Lakhs in FY25 vs ₹1,268.41 Lakhs in FY24, a 58% YoY increase

2 more points management made on profitability & margins

See what OSEL Devices Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

The presentation mentions expanding capacity to drive volume growth and market penetration (Page 21), but does not specify exact capex amounts or project timelines.
Company owns 15,000 sq.ft total capacity for LED Displays and Devices, and a production capacity of 400,000 hearing aids per annum (Page 5), indicating current operational scale.
No explicit new plant, project, or capex figures are detailed in the presentation.
The focus is on in-house R&D investment to offer innovative & cost-effective products, but no specific financial or timeline details given (Page 21).

2 more points management made on capital expenditure plans

Top-ranked in Healthcare Equipment & Supplies

Ranked on what management guided this quarter

5x potential

1Q-Line Biotech Ltd₹1.6K Cr

Rev 2Mar 1

2Vaidya Sane Ayurved Laboratories Ltd₹168 Cr

Rev 2Mar 1

3₹14.4K Cr

Rev 2Mar 3

4₹179 Cr

Rev 2Mar 3

5₹719 Cr

Rev 3Mar 2

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

The Balance Sheet on Page 25 shows changes in borrowings between FY24 and FY25:
Long term borrowings decreased from ₹793.43 Lakhs (FY24) to ₹162.92 Lakhs (FY25).
Short term borrowings increased from ₹1,751.79 Lakhs (FY24) to ₹4,794.71 Lakhs (FY25).
No explicit mention or details of any fundraising through new debt or equity issuance are provided in the presentation.
Share capital increased from ₹1,153.82 Lakhs (FY24) to ₹1,612.92 Lakhs (FY25), indicating possible equity infusion, but this is not directly stated as fundraising.

2 more points management made on fundraising & capital structure

See what OSEL Devices Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The investor presentation does not explicitly mention or report any specific figures or details regarding: - Order book size - Order inflow - Pending orders No direct data or commentary on the current backlog or inflow of customer orders is provided within the presentation content. The focus is primarily on financial performance, market opportunities, products, certifications, growth drivers, and operational strengths.

What OSEL Devices Ltd's management said in earlier quarters

Others in Healthcare Equipment & Supplies this season

QMS Medical (Q1 FY26)
25 crores in FY'26. Key concall takeaways from QMS Medical Allied Services Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
Laxmi Dental (Q1 FY26)
68 crores over two years planned to support expansion. Key concall takeaways from Laxmi Dental Ltd's Q1 FY26 earnings call — and how it ranks against sector…

Compare:vs Poly Medicure Ltd vs Molbio Diagnosti vs Fischer Medical Ventures Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were OSEL Devices Ltd Q1 FY26 results?

What is OSEL Devices Ltd share price analysis?

OSEL Devices Ltd currently shows a neutral. The stock trades at a P/E of 22.1 with a market cap of ₹648 Cr. Investors should review the full earnings analysis for detailed insights.

Is OSEL Devices Ltd planning capital expenditure?

The presentation mentions expanding capacity to drive volume growth and market penetration (Page 21), but does not specify exact capex amounts or project timelines.

Keep OSEL Devices Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.